Mainz Biomed N.V. (MYNZ)

Dec 19, 2024, 8:01 AM EST - 4 weeks ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 16, 2024, 5:00 PM EST - 4 weeks ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 12, 2024, 8:00 PM EST - 5 weeks ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 3, 2024, 2:40 PM EST - 6 weeks ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Nov 29, 2024, 8:45 AM EST - 7 weeks ago

Mainz Biomed Announces Stock Split

Oct 21, 2024, 8:01 AM EDT - 3 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 8:01 AM EDT - 3 months ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 1, 2024, 8:01 AM EDT - 3 months ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Sep 18, 2024, 8:01 AM EDT - 4 months ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 4, 2024, 4:01 AM EDT - 4 months ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024, 8:01 AM EDT - 6 months ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024, 3:01 AM EDT - 6 months ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024, 8:01 AM EDT - 7 months ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Jun 3, 2024, 8:01 AM EDT - 8 months ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

May 31, 2024, 5:01 PM EDT - 8 months ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 28, 2024, 8:01 AM EDT - 8 months ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 20, 2024, 8:01 AM EDT - 8 months ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 7, 2024, 8:01 AM EDT - 9 months ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Apr 25, 2024, 9:29 AM EDT - 9 months ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 9, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mar 19, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 18, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 12, 2024, 8:01 AM EDT - 11 months ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 5, 2024, 8:01 AM EST - 11 months ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Feb 27, 2024, 8:01 AM EST - 11 months ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 22, 2024, 8:01 AM EST - 11 months ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 21, 2024, 8:01 AM EST - 11 months ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 6, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Jan 11, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Dec 19, 2023, 3:39 PM EST - 1 year ago

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Dec 19, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Dec 12, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Dec 5, 2023, 9:01 AM EST - 1 year ago

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Nov 29, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Nov 20, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 16, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 15, 2023, 9:01 AM EST - 1 year ago

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

Nov 13, 2023, 9:00 AM EST - 1 year ago

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

Nov 9, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Nov 7, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

Oct 31, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

Oct 26, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Oct 18, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Oct 11, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Oct 5, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

Oct 4, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

Sep 27, 2023, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

Sep 20, 2023, 3:01 AM EDT - 1 year ago

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2023, 3:01 AM EDT - 1 year ago

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%